Skip to main content
Equibles
ALNY logo

ALNY · Alnylam Pharmaceuticals, Inc.

Track ALNY — free

Use ALNY with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALNY

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$236.01 -0.21 (-0.09%) At close · Aug 24
Market Cap
$31.61B
Shares
133.81M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$236.01 Open$235.83 Day$228.59–237.91 52W close$205.48–491.22 Avg vol 30d2.0M Short int4.8M · 3.6% float · 2.2d Short vol59% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 29, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 15.9 · calm Equity put/call 0.68
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −29%
      below
      Price vs 50-day avg −11%
      below
      RSI (14) 47
      neutral
      MACD trend Positive
      52-week position 11%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −15%
      trailing
      6-month return −26%
      trailing
      YTD return −41%
      this year
      Relative strength −38%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $266 › 200d $330 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +88 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.59% of float · ▼ -16.8% MoM · 2.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      786 holders — mid 3-yr range
      Squeeze score 37
      low risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +23%
      Y/Y
      EPS growth +207%
      Y/Y
      Free cash flow $465.4M
      Balance sheet $981.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 46%
      annualized · 1-yr
      Max drawdown −58%
      past year
      ATR 5.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 30, 2026
      Net product revenues growth vs. 2025 at currency exchange rates · Full-year 2026 Initiated 57% – 71%
      Net product revenues growth vs. 2025 at constant exchange rates · Full-year 2026 Initiated 57% – 70%
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Net product revenues growth vs. 2024 at currency exchange rates · Full-year 2025 79% – 85%
      GAAP R&D and SG&A expenses · Full-year 2025 $2.5B – $2.58B
      Non-GAAP R&D and SG&A expenses · Full-year 2025 $2.15B – $2.2B
      Guided vs delivered · last 1 settled
      Combined net product revenues for our four commercialized produc full year 2023
      guided $1.2B – $1.29B
      $1.83B Beat +47.1%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −29% Bearish
      Price vs 50-day avg
      −11% Bearish
      RSI (14)
      47 Neutral
      MACD trend
      Positive Bullish
      52-week position
      11% Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $266 › 200d $330 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +88 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.59% of float · ▼ -16.8% MoM · 2.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      786 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $205 Now $236 · 11% Range high $491
      vs 200-day avg -29% vs 50-day avg -11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Total Rare net product revenues 141.89M Three Months Ended June 30, 2026 —
      Total Rare net product revenues % Change 11% Three Months Ended June 30, 2026 —
      Total TTR net product revenues 1.03B Three Months Ended June 30, 2026 —
      Total TTR net product revenues % Change 89% Three Months Ended June 30, 2026 —
      Total TTR net product revenues % Change At CER non-GAAP 89% Three Months Ended June 30, 2026 —
      AMVUTTRA net product revenue growth at constant currency non-GAAP 183% Three Months Ended March 31, 2026 —
      GIVLAARI net product revenue growth at constant currency non-GAAP 7% Three Months Ended March 31, 2026 —
      Non-GAAP Income from operations non-GAAP 338.79M Three Months Ended March 31, 2026 —
      Non-GAAP Net income non-GAAP 273.04M Three Months Ended March 31, 2026 —
      Non-GAAP Net income per common share - diluted non-GAAP $1.99 Three Months Ended March 31, 2026 —
      Non-GAAP Net income per common share — basic non-GAAP $2.05 Three Months Ended March 31, 2026 —
      Non-GAAP Research and development expenses non-GAAP 334.75M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP Research and development expenses 364.87M
      -30.11M Less: Stock-based compensation expenses
      = Non-GAAP Research and development expenses 334.75M
      Non-GAAP Selling, general and administrative expenses non-GAAP 282.51M Three Months Ended March 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP Selling, general and administrative expenses 322.55M
      -40.04M Less: Stock-based compensation expenses
      = Non-GAAP Selling, general and administrative expenses 282.51M
      ONPATTRO net product revenue growth at constant currency non-GAAP -61% Three Months Ended March 31, 2026 —
      OXLUMO net product revenue growth at constant currency non-GAAP 13% Three Months Ended March 31, 2026 —
      Total net product revenue growth at constant currency non-GAAP 117% Three Months Ended March 31, 2026 —
      Total Rare net product revenue growth at constant currency non-GAAP 10% Three Months Ended March 31, 2026 —
      Total revenue growth at constant currency non-GAAP 93% Three Months Ended March 31, 2026 —
      Total TTR net product revenue growth at constant currency non-GAAP 150% Three Months Ended March 31, 2026 —
      Non-GAAP Net income (loss) per common share — diluted non-GAAP $1.25 Q4 2025 —
      Non-GAAP Net income (loss) per share — diluted non-GAAP $5.08 Full Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ALNY
      Alnylam Pharmaceuticals, Inc.
      this stock
      		$31.61B -40.6% +22.9% — 3.6%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.91B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $85.30B +7.3% +20.8% 20.5 3.3%
      ARGX
      Argenx SE
      		 $64.66B +20.2% — — 2.1%
      CSLLY
      Csl Ltd
      		 $57.97B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      786
      % held
      101.1%
      Net QoQ
      +4.7M sh
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      758
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.8M
      Days to cover
      2.2d
      Change
      -970.2K sh
      View
      Short Volume
      Short vol %
      59%
      As of
      Aug 24, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      65
      Value
      $13.4K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      46.8%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Jefferson Shreve
      Amount
      $15.0K–$50.0K
      Traded
      May 12, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $3.7B
      Net income (FY)
      $313.7M
      EPS diluted
      $2.33
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $1.1M
      Shares
      3.8K
      Filed
      Jun 1, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ALNY +5.1% -15.2% -25.9% +14.8% -40.7%
      SPY -1.2% +3.3% +12.2% +2.2% +12.0%
      vs SPY +6.3% -18.5% -38.2% +12.6% -52.6%
      Key facts CIK 1178670 CUSIP 02043Q107 13F (30d) 689 filings 645 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)